Selumetinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 764 publications

Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review.

Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review.

Journal: International journal of surgical pathology
Published: May 14, 2026

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.

Journal: Neuro-oncology advances
Published: April 30, 2026

Using Patient iPSC-derived Retinal Pigment Epithelial Cells to Evaluate Differential Susceptibility to MEK Inhibitor-Associated Retinopathy.

Using Patient iPSC-derived Retinal Pigment Epithelial Cells to Evaluate Differential Susceptibility to MEK Inhibitor-Associated Retinopathy.

Journal: bioRxiv : the preprint server for biology
Published: April 27, 2026

Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis.

Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis.

Journal: Clinical neurology and neurosurgery
Published: March 31, 2026

Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1.

Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1.

Journal: Journal of neuro-oncology
Published: March 29, 2026

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies.

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies.

Journal: Journal of neuro-oncology
Published: March 27, 2026

Mechanical Stiffening Promotes Growth, Invasion-Associated Phenotypes, and Reduced Selumetinib Sensitivity in 3D Plexiform Neurofibroma Cultures.

Mechanical Stiffening Promotes Growth, Invasion-Associated Phenotypes, and Reduced Selumetinib Sensitivity in 3D Plexiform Neurofibroma Cultures.

Journal: Cells
Published: March 27, 2026

TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines.

TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines.

Journal: microPublication biology
Published: March 20, 2026

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Journal: Expert review of anticancer therapy
Published: March 12, 2026

Patient and caregiver experiences with selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Patient and caregiver experiences with selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

Journal: Neuro-oncology practice
Published: March 09, 2026

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.

Journal: Oncology reviews
Published: February 23, 2026

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Showing 1-12 of 764

Last Updated: 06/30/2026